leisure time -WSS

leisure time

author：fashion 2025-09-29 16:35:08 - browse：15341

Blue CAR-T cell attacks a leukemia cell. --health coverage from STAT — Engineered receptors on the surface of a T-lymphocyte bind to a leukemia cell. Adobe

The announcement on Tuesday that the Food and Drug Administration was investigating whether CAR-T immunotherapy had itself caused blood cancers initially appeared to be a significant blow to one of the brightest spots in cancer care.

But experts quickly cautioned that risk of this complication is probably minuscule compared to the known risk of secondary cancers from other cancer therapies like chemotherapy and radiation. They noted that CAR-T cells are immune cells that are genetically engineered to fight cancer, and that such genetic modifications were long thought to carry a risk of causing a second, new cancer in patients. The surprise, in a way, is that since CAR-T was first invented more than 10 years ago, that risk had remained just theoretical.

“There’s been a requirement for long-term follow up. I think this is why we’re all surprised. As far as I think any one of us knew, it’d never happened with any of the FDA-approved CAR-Ts,” said Marcela Maus, a cell therapy researcher at Mass General Cancer Center.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Researchers CRISPR chickens in bid to protect them from bird flu

entertainment

explore

WSS

Protect nursing home residents from future pandemics

STAT Readout: Today's biotech news includes Sana and Amylyx

Guardant Health colon cancer test endorsed by FDA advisory panel

Better Therapeutics data on benefit with GLP

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

leisure time

leisure time

entertainment

Cancer drug shortages should be causing more outrage

Humana CEO Bruce Broussard to step down in 2024

Dobbs anniversary: the lost opportunity of abortion as health care

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

As demand for Covid shots wanes, Moderna seeks its next success

What's changing in Medicare's open enrollment this year?

Activists slam private health insurers over coverage restrictions

Clinicians often fail to acknowledge the pain caused by long Covid

What does generative AI mean for health care? We asked experts

Nick Jonas talks about managing diabetes along with his career

leisure time

Pharma’s losing bet in New Jersey

What the Wegovy shortage looks like for doctors — and for patients

European regulators recommend Amylyx's ALS drug be rejected

European regulators recommend Amylyx's ALS drug be rejected

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Decentralized clinical trials need collaboration to achieve wider use

entertainment

entertainment

explore

hotspot